Raul Cordoba/X
Jun 29, 2025, 14:28
Raul Cordoba Highlights Study on Performance of CHA2DS2-VASc and HAS-BLED in Predicting Stroke and Bleeding in Atrial Fibrillation and Cancer
Raul Cordoba, Associate Chief at the Department of Hematology at Jiménez Díaz Foundation, shared a post on X:
“Performance of CHA2DS2-VASc and HAS-BLED in predicting stroke and bleeding in atrial fibrillation and cancer.
“The CHA2DS2-VASc score had good to modest discrimination in haematological cancer AUC = 0.71 (0.66, 0.76), compared with no-cancer AUC = 0.73 (0.72, 0.74)
HAS-BLED discrimination was poor in haematological cancer AUC = 0.59 (0.55, 0.64), compared with no-cancer AUC = 0.61 (0.60, 0.62)”
Title: Performance of CHA2DS2-VASc and HAS-BLED in predicting stroke and bleeding in atrial fibrillation and cancer
Authors: Alyaa M Ajabnoor, Salwa S Zghebi, Rosa Parisi, Darren M Ashcroft, Corinne Faivre-Finn, Mamas A Mamas, Evangelos Kontopantelis
Read the full article.
Stay updated with Hemostasis Today.
-
Apr 13, 2026, 17:41Peter Zdziarski: Glanzmann’s Research Foundation Listed as GT Patient Organization on NORD
-
Apr 13, 2026, 17:39Nathan Connell: Why Prophylaxis in vWD Has Historically Lagged Behind Established Practice in Hemophilia
-
Apr 13, 2026, 17:38Tareq Abadl: A Blood Transfusion Can Cause a Delayed Platelet Crash
-
Apr 13, 2026, 13:33Tetsumei Urano: Join for the ISTH Educational Programs at APSTH 2026 in Japan
-
Apr 13, 2026, 13:26Salih Ehsan: Neutrophil Behavior Across Pregnancy and Infection Assessment
-
Apr 13, 2026, 13:20Denis Oduor: Autologous Blood Transfusion – A Significant Moment in Patient Care and Choice
-
Apr 13, 2026, 13:13Tareq Abadl: How the Immune System Turns Against the Body in Autoimmune Diseases
-
Apr 13, 2026, 13:13Yousra Tera: Celebrating a Lasting Impact on Future Generations
-
Apr 13, 2026, 13:07Laura Dormer: Real-World Insights into Treatment and Costs in VWD from FORvWARD Study